期刊文献+

血清CA125和OPN联检在卵巢癌患者中的诊断价值 被引量:7

Evaluation of Selected Serum Proteins CA125 and OPN as Diagnosis of Ovarian Cancer
原文传递
导出
摘要 目的:探讨CA125和OPN联检在卵巢癌诊断中的应用价值。方法:以50例正常健康人为对照,对经组织病理学确诊的69例卵巢癌患者和54例卵巢良性肿瘤患者术前行血清CA125(放免法)和OPN(ELISA法)测定。比较二种血清标志物在正常人、卵巢良性肿瘤和卵巢癌病例中的表达水平。以正常人血清OPN均值±1.96S作为上下界,计算OPN临界值,大于临界值即为OPN阳性。血清CA125≥35 U/mL为阳性。比较三组病例中血清CA125和OPN单检及联检的灵敏度及特异性。比较二种血清标志物在卵巢癌及卵巢良性肿瘤的不同组织分型中的灵敏度。结果:卵巢癌组血清CA125和OPN的水平均显著高于正常对照组和卵巢良性肿瘤组(P<0.01),OPN临界值为27 ng/mL。在卵巢癌诊断中CA125、OPN检测的敏感度分别为66.7%和85.5%,二者联检的敏感度为95.7%。同时二者联检对浆液性囊腺癌、粘液性囊腺癌和子宫内膜样腺癌的敏感度分别为91.7%、70.0%和66.7%。结论:血清CA125和OPN是卵巢癌诊断的敏感性指标,二者联检可提高卵巢癌、特别是粘液性卵巢癌诊断的敏感度。 Objective:To evaluate the value of serum proteins CA125 and OPN as diagnosis of ovarian cancer.Methods: The expression of serum CA125 and OPN in 69 patients with ovarian cancer,54 patients with ovarian benign tumor and 50 normal persons were detected by RIA and ELISA.The concentration of serum E2 and SO were examined by ELISA and the relationship was analyzed.We contrasted the sensitivity and specificity of combined determination of CA125 and OPN in three groups.We contrasted the sensitivity of combined determination of CA125 and OPN in different pathologic-types of ovarian cancer.Results: The serum CA125 and OPN in cancer group is higher expressed than the other two groups,with statistical significance(P 〈 0.01).The sensitivities of CA125 and OPN are 66.7% and 85.5% in the diagnosis of ovarian cancer,the combined determination one is 95.7%.In patients with ovarian serous adenocarcinoma,mucous adenocarcinoma and endometrioid adenocarcinoma,the sensitivities of combined determination of CA125 and OPN are 91.7%,70.0% and 66.7%.Conclusion: The measurement of serum CA125 and OPN is an effective method in the diagnosis for patients with ovarian cancer.The positive rate can be increased by the combined use of CA125 and OPN for patients with mucous adenocarcinoma.
出处 《现代生物医学进展》 CAS 2012年第9期1742-1744,共3页 Progress in Modern Biomedicine
关键词 卵巢癌 CA125 OPN Ovarian cancer; CA125; OPN;
  • 相关文献

参考文献15

  • 1Diamandis EP.Cancer biomarkers:can we turn recent failures intosuccess?[J].J Natl Cancer Inst,2010,102(19):1462-1467. 被引量:1
  • 2Urban P,Bilecová-RabajdováM,StefekováZ,et al.Overview ofpotential oncomarkers for detection of early stages of ovarian cancer[J].Klin Onkol,2011,24(2):106-111. 被引量:1
  • 3Hellstrom I,Hellstrom KE.Two novel biomarkers,mesothelin andHE4,for diagnosis of ovarian carcinoma[J].Expert Opin Med Diagn,2011,5(3):227-240. 被引量:1
  • 4Benjapibal M,Neungton C.Pre-operative prediction of serum CA125level in women with ovarian masses[J].J Med Assoc Thai,2007,90(10):1986-1991. 被引量:1
  • 5Kurdoglu Z,Gursoy R,Kurdoglu M,et al.Comparison of the clinicalvalue of CA 19-9 versus CA 125 for the diagnosis of endometriosis[J].Fertil Steril,2009,92(5):1761-1763. 被引量:1
  • 6Cabar FR,Fettback PB,Pereira PP,et al.Serum markers in the diagno-sis of tubal pregnancy[J].Clinics(Sao Paulo),2008,63(5):701-708. 被引量:1
  • 7Bataller SifréR,Guiral Olivan V,Fernández Rodríguez C,et al.The term"tumor marker"under revision.Report of a patient demon-strating such need(liver cirrhosis and CA 125)[J].Rev Esp EnfermDig,2008,100(11):734-736. 被引量:1
  • 8Zhu W,Michael CW.WT1,monoclonal CEA,TTF1,and CA125 anti-bodies in the differential diagnosis of lung,breast,and ovarian adeno-carcinomas in serous effusions[J].Diagn Cytopathol,2007,35(6):370-375. 被引量:1
  • 9Song G,Cai QF,Mao YB,et al.Osteopontin promotes ovarian cancerprogression and cell survival and increases HIF-1alpha expressionthrough the PI3-K/Akt pathway[J].Cancer Sci,2008,99(10):1901-1907. 被引量:1
  • 10Anborgh PH,Mutrie JC,Tuck AB,et al.Pre-and post-translationalregulation of osteopontin in cancer[J].J Cell Commun Signal,2011,5(2):111-122. 被引量:1

二级参考文献27

  • 1Maeda T, Inoue M, Koshiba S, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125(MUC16) [J]. J Biol Chem, 2004, 279( 13): 13174-13182. 被引量:1
  • 2Benjapibal M, Neungton C. Pre-operative prediction of serumCA125 level in women with ovarian masses [J]. J Med Assoc Thai, 2007, 90( 10): 1986-1991. 被引量:1
  • 3Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer [J]. J Clin Oncol, 2005, 23 (31 ): 7919-7926. 被引量:1
  • 4Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [J ]. Gynecol Oncol, 2008, 108 (2):402-408. 被引量:1
  • 5Zhang Z, Yu Y, Xu F, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer [J ]. Gynecol Oncol, 2007, 107(3): 526-531. 被引量:1
  • 6Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer [J]. Clin Cancer Res, 2008, 14 (4): 1065-1072. 被引量:1
  • 7Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer [J]. Cancer Epidemiol Biomarkers Prey, 2008, 17(10): 2872-2881. 被引量:1
  • 8Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas [J]. Cancer Res, 2005, 65 (6): 2162-2169. 被引量:1
  • 9Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients [J]. Clin Cancer Res, 2005, 11 ( 10): 3814-3820. 被引量:1
  • 10Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer[J]. Clin Cancer Res, 2006, 12(2): 447-453. 被引量:1

共引文献49

同被引文献63

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部